微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志

• 论文 • 上一篇    下一篇

三阴性乳腺癌化疗疗效及预后分析

曹轶林;徐李容;屈元姣;秦日昇;陈熙;彭丽芳;申昊;   

  1. 广西壮族自治区第二人民医院肿瘤科;
  • 收稿日期:2009-03-25 修回日期:2009-03-25 出版日期:2009-03-25 发布日期:2009-03-25

Analysis on prognosis and response to chemotherapy of triplenegative breast cancer

CAO Yi-lin,XU Li-rong,QU Yuan-jiao,et al.   

  1. (Department of Medical Oncology,The Second Hospital of GuangXi Zhuang automomous Region,Guilin 541002,China
  • Received:2009-03-25 Revised:2009-03-25 Online:2009-03-25 Published:2009-03-25

赞

被引次数

15

摘要： 目的探讨三阴性乳腺癌化疗疗效及与预后的关系。方法147例晚期乳腺癌患者用免疫组化法筛选雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(Her-2)均为阴性的三阴性乳腺癌,化疗方案为紫杉醇135mg/m~2(或多西他赛75mg/m~2)静注,d1;顺铂30mg/m~2,静滴,d1～3。21d为1个周期,2个周期后评价疗效,分析三阴性乳腺癌及非三阴性乳腺癌临床病理特征、疗效及预后。结果147例患者中20例(13.6%)为三阴性乳腺癌,三阴性乳腺癌原发灶大小与非三阴性乳腺癌的差异有统计学意义(P=0.042),余临床病理特征无明显差异;三阴性乳腺癌化疗有效率(55.0%)高于非三阴性乳腺癌(32.3%,P=0.048),但中位肿瘤进展时间分别为5.5月和6.5月。结论紫杉醇(或多西他赛)联合顺铂对三阴性乳腺癌较敏感,但中位肿瘤进展时间则劣于非三阴乳腺癌。

关键词: 乳腺肿瘤, 雌激素受体, 孕激素受体, 表皮生长因子受体-2, 化学疗法

Abstract: Objective To evaluate the response to chemotherapy and the prognosis of triple-negative breast cancer(TNBC)by comparing to the non-TNBC.Methods 147 advanced breast carcinoma patients were defined negative expresions of estrogenr eceptor(ER),progesterone receptor(PR) and human epidermal growth factor rector 2(Her-2 ) by immunohistochemistry. Paclitaxel or Docetaxel was administered intravenously at a dose of 135mg/m~2(or 75 mg/m~2)on d1,Cisplatin 30mg/m~2 from d1 to d3.A treatment cycle was 21 days.After 2 cycles,the pathologic parameters,the treatment efficacy and the prognosis were compared between the patients of TNBC and non-TNBC.Results 20 of 147 patients(13.6%) were TNBC.Patients of TNBC had higher overall response rate compared with non-TNBC(P = 0.048 ).The median progression free survial time in the patients of TNBC and non-TNBC were 5.5 months and 6.5 months respectively.There were significant difference between the two groups at primary tumor size(P =0.042).Conclusion Paclitaxel or Docetaxel combined with Cisplatin chemotherapy regimen was sensitive in TNBC,but the median progression free survial time was worse in this group.

Key words: Breast neoplasma, ER, PR, Her-2, Chemotherapy